GlassScriptPhysician profile
Katsiaryna V Chuprasava
NPI 1851504641
$5,378.22
in general payments reported to CMS, 2019-2025
35 companies · $795 in 2025
The $795 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $990 · 2020: $1,203 · 2021: $146 · 2022: $787 · 2023: $848 · 2024: $610 · 2025: $795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,244 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,243.87 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $803.78 | 2022-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $722.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $495.54 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $489.30 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $458.87 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $424.44 | 2019-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $373.46 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $246.25 | 2019-2025 | |
| Allergan, INC. | $156.29 | 2020 | |
| Exact Sciences Corporation | $118.21 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $117.88 | 2019-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $102.04 | 2019-2023 | Steglatro, Belsomra |
| Astellas Pharma US INC | $86.22 | 2019-2025 | Veozah |
| Dexcom, INC. | $79.64 | 2021-2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.87 | 2022-2024 | Xifaxan |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $68.51 | 2019-2022 | |
| Amarin Pharma, INC. | $58.54 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.91 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $50.65 | 2022 | |
| Idorsia Pharmaceuticals US INC | $46.68 | 2022-2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $40.86 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $36.64 | 2020 | |
| Eisai INC. | $33.12 | 2020 | |
| Axsome Therapeutics, INC. | $28.97 | 2025 | Symbravo |
| Inspire Medical Systems, INC. | $23.33 | 2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $22.99 | 2020 | |
| Shield Therapeutics INC | $21.86 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $21.62 | 2021 | |
| Xeris Pharmaceuticals, INC. | $21.43 | 2023 | Gvoke Hypopen |
| Horizon Therapeutics Plc | $19.96 | 2020 | |
| Vivus LLC | $19.10 | 2024 | Qsymia |
| Teva Pharmaceuticals USA, INC. | $19.00 | 2022 | |
| Almatica Pharma LLC | $16.66 | 2023 | Loreev Xr |
| Ethicon US, LLC | $16.02 | 2022 | |
| Bausch Health US, LLC | $14.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katsiaryna Chuprasava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.